Pacylex submitted two abstracts for presentation at the 2019 American Association for Cancer Research (AACR) conference and both have been accepted. The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world. (https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=174#.W4CWn-hKiUk) The AACR annual conference will be held in Atlanta, Georgia March 29 - Apr 3, 2019.
“Examination of NMT1 and NMT2 as independent prognostic markers and novel drug targets in adult acute myeloid leukemia” and “Targeting N-myristoylation in B cell lymphomas as a therapeutic strategy” will be presented as a Poster Session at the AACR Annual Meeting and will be published in the 2019 Proceedings of the AACR. Both posters will be presented in a session on Experimental and Molecular Therapeutics with a title of: New Target Identification. Additional details concerning their presentation are below:
Session Date and Time: Tuesday Apr 2, 2019 8:00 AM - 12:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 13
3043 = Examination of NMT1 and NMT2 as independent prognostic markers and novel drug targets in adult acute myeloid leukemia
3046 = Targeting N-myristoylation in B cell lymphomas as a therapeutic strategy
The mission of the American Association for Cancer Research is to prevent and cure cancer through research, education, communication, collaboration, funding, and advocacy. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.